Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Antisense DNA Therapy

  • Bruno Calabretta
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_335-2


Antisense DNA therapy refers to the introduction of short antisense strands of DNA, which then bind with target mRNA. Many cancers are due to overexpression of the genes that promote cell proliferation, called tumor suppressor genes. Antisense RNA might be able to inhibit this overexpression. Antisense DNA is single-stranded DNA of various lengths that is complementary to the mRNA of a given gene. The antisense DNA binds to the mRNA and, by mechanisms that are not completely understood, inhibits its natural function, i.e., translation into protein. Antisense nucleic acids are widely used to study the effect of genes in cultured cells. The potential of antisense nucleic acids in gene therapy, for instance to therapeutically downregulate the expression of overexpressed genes, is being evaluated.


It is increasingly clear that the process of tumorigenesis is intimately associated with the accumulation of specific genetic abnormalities. This recognition has led to...


Chronic Myeloid Leukemia Chronic Myelogenous Leukemia Autologous Bone Marrow Chronic Myelogenous Leukemia Patient Antileukemia Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Beltinger C, Saragovi HU, Smith RM et al (1995) Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 95:1814CrossRefPubMedPubMedCentralGoogle Scholar
  2. Gewirtz AM, Sokol DL, Ratajczak MZ (1998) Nucleic acid therapeutics: state of the art and future prospects. Blood 92:712–736PubMedGoogle Scholar
  3. Milner N, Mor KU, Southern EM (1997) Selecting effective antisense reagents on combinatorial oligonucleotide assays. Nat Biotechnol 15:537–541CrossRefPubMedGoogle Scholar
  4. Pagnan G, Stuart DD, Pastorino F et al (2000) Delivery of c-myb antisense oligodeoxy-nucleotides to human neuroblastoma cells via disialoganglioside GD2-targeted immunoliposomes: antitumor effects. J Natl Cancer Inst 92:253CrossRefPubMedGoogle Scholar
  5. Skorski T, Nieborowska-Skorska M, Nicolaides NC et al (1994) Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci U S A 91:4504CrossRefPubMedPubMedCentralGoogle Scholar
  6. Webb A, Cunningham D, Cotter F et al (1997) BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349:1137–1141CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Kimmel Cancer InstituteThomas Jefferson UniversityPhiladelphiaUSA